scholarly journals Signs and symptoms associated with primary tooth eruption: a clinical trial of nonpharmacological remedies

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Mahtab Memarpour ◽  
Elham Soltanimehr ◽  
Taherh Eskandarian
Keyword(s):  
Clinical Trial ◽  
Signs And Symptoms ◽  
Tooth Eruption ◽  
Primary Tooth

Signs and Symptoms of Primary Tooth Eruption: A Meta-analysis

PEDIATRICS ◽  
2016 ◽  
Vol 137 (3) ◽  
pp. e20153501 ◽  
Author(s):  
Carla Massignan ◽  
Mariane Cardoso ◽  
André Luís Porporatti ◽  
Secil Aydinoz ◽  
Graziela De Luca Canto ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Signs And Symptoms ◽  
Tooth Eruption ◽  
Primary Tooth

scholarly journals Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial

2019 ◽  
Vol 37 (1) ◽  
pp. 329-341 ◽  
Author(s):  
Martin Kallab ◽  
Stephan Szegedi ◽  
Nikolaus Hommer ◽  
Hannes Stegmann ◽  
Semira Kaya ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Dry Eye ◽  
Low Dose ◽  
Signs And Symptoms ◽  
Preservative Free

scholarly journals Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections

2021 ◽  
Author(s):  
Aldo A M Lima ◽  
Erico A G Arruda ◽  
Roberto J Pires-Neto ◽  
Melissa S Medeiros ◽  
J Quirino-Filho ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin C ◽  
Respiratory Infection ◽  
Clinical Symptoms ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Clinical Suspicion ◽  
Pharmacological Intervention ◽  
Controlled Clinical Trial ◽  
Double Blind

This study aimed to evaluate the efficacy and toxicity of tenofovir (TDF) and TDF combined with emtricitabine (TDF/FTC) in patients with mild to moderate COVID-19 infections. We conducted a randomized, double-blind, placebo-controlled clinical trial in patients with clinical suspicion of mild to moderate respiratory infection caused by SARS-CoV-2 who were treated at an outpatient clinic. Patients were randomly recruited to take 10 days of TDF (300 mg/day), TDF (300 mg/day) combined with FTC (200 mg/day) or placebo Vitamin C (500 mg/day). The primary parameter was the score of symptoms and predictive signs of COVID-19, assessed on the seventh day of patient follow-up. From a total of 309 patients with clinical suspicion of SARS-CoV-2, 227 met the inclusion criteria and were randomly distributed into the following groups: (a) 75 (one did not initiate treatment) in the TDF group; (b) 74 in the TDF combined with FTC group; and (c) 77 in the Vitamin C group (placebo). Of the 226 patients, 139 (62%) were positive for SARS-CoV-2. Fever (37.8oC), ageusia or dysgeusia, anosmia or dysosmia, and two or more clinical symptoms or signs were significantly associated with SARS-CoV-2 infection. There was no significant change in clinical score based on clinical symptoms and signs between treatment groups. Patients with mild to moderate infection by SARS-CoV-2 had higher concentrations of G-CSF, IL-1β, IL-6 and TNF-α compared to patients without infection. Patients with mild to moderate respiratory infection, with fever (37.8oC), loss of smell, loss of taste and two or more symptoms, have a better prediction for the diagnosis of COVID-19. Patients with SARS-CoV-2 showed higher and more persistent proinflammatory cytokines profile compared to patients not infected with SARS-CoV-2. Pharmacological intervention with TDF or TDF combined with FTC did not change the clinical signs and symptoms score in mild to moderate respiratory infection in patients with SARS-CoV-2 compared to the Vitamin C group (placebo).

Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT

2006 ◽  
Vol 8 (5) ◽  
pp. 502-508 ◽  
Author(s):  
Maylene Wong ◽  
Lidia Staszewsky ◽  
Elisa Carretta ◽  
Simona Barlera ◽  
Roberto Latini ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Chronic Heart Failure ◽  
Point Of Care ◽  
Signs And Symptoms ◽  
Clinical Trial Results

Effect of Silymarin in the Treatment of Allergic Rhinitis

2011 ◽  
Vol 145 (6) ◽  
pp. 904-909 ◽  
Author(s):  
Mehdi Bakhshaee ◽  
Farahzad Jabbari ◽  
Saeed Hoseini ◽  
Reza Farid ◽  
Mohammad Hadi Sadeghian ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Randomized Clinical Trial ◽  
Signs And Symptoms ◽  
Study Group ◽  
Positive Skin Prick Test ◽  
Serum Ige ◽  
Oxidative Stresses ◽  
The Impact

Objective. Although the role of oxidative stresses has been confirmed in the pathophysiology of allergic rhinitis and the protective effect of silymarin against oxidative stresses has been proven in different organs, no study has yet been conducted on the impact of silymarin on allergic rhinitis treatment. Study Design. A randomized clinical trial study. Setting. Two tertiary referral centers with otorhinolaryngology–head and neck surgery and allergy and immunology departments. Patients and Methods. In a randomized clinical trial, 94 patients with the signs and symptoms of allergic rhinitis and a positive skin prick test were selected and randomly divided into 2 groups. Their signs and symptoms, eosinophil percentage on nasal smear, serum IgE, and interleukin (IL-4, IL-5, interferon-γ) levels were recorded. The study group was treated with silymarin, whereas the control group received placebo, both for 1 month, along with routine antihistamine treatment. At the end of the treatment course, clinical and laboratory findings were statistically analyzed. Results. Sixty patients completed the trial. Based on the Sino-Nasal Outcome Test 20 (SNOT-20), a significant improvement in clinical symptom severity was observed in both groups (9.23 ± 5.14 vs 2.20 ± 2.69; P < .001), which was statistically significantly higher in the study group ( P < .001). Posttreatment percentage of nasal eosinophils and cytokine levels showed no significant difference ( P > .05). Rise in serum IgE level was seen after treatment with silymarin ( P = .003). Conclusion. Considering the statistically effective role of silymarin in alleviating the severity of allergic rhinitis symptoms, applying this herbal antioxidant along with other medications may result in better management.

scholarly journals A CLINICAL STUDY ON THE MANAGEMENT OF STHAULYA BY TRIKATU CHURNA

2020 ◽  
Vol p4 (05) ◽  
pp. 2382-2388
Author(s):  
Ankur Saxena ◽  
Sunil K Gupta ◽  
Jolly Saxena ◽  
Niranjan S
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Trial ◽  
Clinical Study ◽  
Signs And Symptoms ◽  
Morbidity Rate ◽  
Mortality And Morbidity ◽  
Anxiety Depression ◽  
Positive Results

Sthaulya / Atisthaulya in Ayurveda comes under the heading of Medoroga which results due to dysfunc-tion of Meda Dhatvagni (factor responsible for nourishment / metabolism of Meda dhatu) and in modern parlance it is equated with Obesity due to its close similarities. It is the main cause for so many complica-tions like Hypertension, Diabetes mellitus, Osteoarthritis, Infertility, Impotency etc. as well as psychologi-cal disturbances like anxiety, depression etc. Thus, the mortality and morbidity rate were high in obese per-sons compared to others. This shows the importance of the need for further researches of effective measures in the management of Sthaulya. Hence in the present study a clinical trial was carried out with Trikatu Churna in the management of Sthaulya (obesity) for 30 days. 30 patients were selected with diag-nosis of Sthaulya out of which 24 completed the treatment. The study concluded with the positive results of Trikatu churna in reducing the signs and symptoms of Sthaulya.

Sign in / Sign up

Export Citation Format

Share Document